JP2006511538A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511538A5
JP2006511538A5 JP2004560402A JP2004560402A JP2006511538A5 JP 2006511538 A5 JP2006511538 A5 JP 2006511538A5 JP 2004560402 A JP2004560402 A JP 2004560402A JP 2004560402 A JP2004560402 A JP 2004560402A JP 2006511538 A5 JP2006511538 A5 JP 2006511538A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
formula
compound
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004560402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511538A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/014224 external-priority patent/WO2004054586A1/en
Publication of JP2006511538A publication Critical patent/JP2006511538A/ja
Publication of JP2006511538A5 publication Critical patent/JP2006511538A5/ja
Pending legal-status Critical Current

Links

JP2004560402A 2002-12-16 2003-12-15 非ヌクレオシド系逆転写酵素阻害剤(nnrti)とプロテアーゼ阻害剤などのシトクロムp450の阻害剤とを含む組み合わせの使用 Pending JP2006511538A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43369002P 2002-12-16 2002-12-16
PCT/EP2003/014224 WO2004054586A1 (en) 2002-12-16 2003-12-15 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Publications (2)

Publication Number Publication Date
JP2006511538A JP2006511538A (ja) 2006-04-06
JP2006511538A5 true JP2006511538A5 (enExample) 2007-02-08

Family

ID=32595224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004560402A Pending JP2006511538A (ja) 2002-12-16 2003-12-15 非ヌクレオシド系逆転写酵素阻害剤(nnrti)とプロテアーゼ阻害剤などのシトクロムp450の阻害剤とを含む組み合わせの使用

Country Status (20)

Country Link
US (2) US20040152625A1 (enExample)
EP (1) EP1575595A1 (enExample)
JP (1) JP2006511538A (enExample)
KR (1) KR20050085681A (enExample)
CN (1) CN1726041A (enExample)
AU (1) AU2003296647A1 (enExample)
BR (1) BR0317095A (enExample)
CA (1) CA2510143A1 (enExample)
EA (1) EA200500894A1 (enExample)
EC (1) ECSP055854A (enExample)
HR (1) HRP20050557A2 (enExample)
IL (1) IL169099A0 (enExample)
MX (1) MXPA05005773A (enExample)
NO (1) NO20053455L (enExample)
NZ (1) NZ541187A (enExample)
PL (1) PL376900A1 (enExample)
RS (1) RS20050461A (enExample)
UA (1) UA81003C2 (enExample)
WO (1) WO2004054586A1 (enExample)
ZA (1) ZA200502947B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
US20060287316A1 (en) * 2005-04-27 2006-12-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
WO2007062526A1 (en) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
CN1907138B (zh) * 2006-08-11 2011-01-12 华南师范大学 一种沙田柚子汁提取物及其提取方法和应用
ES2628730T3 (es) 2006-09-21 2017-08-03 Taimed Biologics, Inc. Inhibidores de proteasa
SG174146A1 (en) 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
LT2421527T (lt) * 2009-04-25 2018-09-10 F. Hoffmann-La Roche Ag Farmakokinetinių savybių pagerinimo būdai
CA2761650C (en) 2009-05-13 2015-05-26 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
WO2026093435A1 (en) 2024-10-31 2026-05-07 Institut National de la Santé et de la Recherche Médicale Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2285577A1 (en) * 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
HK1040625B (zh) * 1998-11-04 2005-04-01 法玛西雅厄普约翰美国公司 用於改善替普拉那维的药物动力学的方法
US6391919B1 (en) * 2000-01-12 2002-05-21 Bristol-Myers Squibb Pharma Company Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
TWI270547B (en) * 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
DE60306539T2 (de) * 2002-09-19 2007-07-19 Boehringer Ingelheim (Canada) Ltd., Laval Nicht-nukleosidische inhibitoren der reverse transkriptase

Similar Documents

Publication Publication Date Title
JP2011528713A5 (enExample)
EP2248519A3 (en) Non-mucoadhesive film dosage forms
TW200916103A (en) Therapeutic compositions and methods
JP2021521118A5 (enExample)
WO2007070677A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
JP2010532372A5 (enExample)
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
ES3060114T3 (enExample)
JP2002528502A5 (enExample)
JP2017514911A5 (enExample)
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JPWO2023054732A5 (enExample)
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
JP2009517411A5 (enExample)
JP2007504168A5 (enExample)
JP2023531930A5 (enExample)
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
KR102512494B1 (ko) 의약
JP2024525164A5 (enExample)
RU2007132971A (ru) Способы и материалы с транс-кломифеном для лечения мужского бесплодия
JP2007536359A5 (enExample)
CN110891574B (zh) 用于预防和/或治疗肝细胞癌的美格列明
US20050227949A1 (en) Compositions and methods for treatment of viral and bacterial infections